MedTrace Logo

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

NCT05515289 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-10

No results posted yet for this study

Summary

The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 24-30 subjects.

Subjects will take the SHR6390 on Day1.

Conditions

Interventions

DRUG

SHR6390

SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-18
Primary Completion
2023-08-28
Completion
2023-09-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05515289 on ClinicalTrials.gov